分组1 - Assertio reported a quarterly loss of $1.86 per share, which was better than the Zacks Consensus Estimate of a loss of $3.05, representing an earnings surprise of +39.02% [1] - The company posted revenues of $13.54 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 185.10%, although this is a decline from year-ago revenues of $32.18 million [2] - Assertio has surpassed consensus EPS estimates two times and revenue estimates three times over the last four quarters [2] 分组2 - The stock has increased by approximately 27.2% since the beginning of the year, contrasting with a 3.1% decline in the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$2.28 on revenues of $9.3 million, and for the current fiscal year, it is -$0.28 on revenues of $112.23 million [7] - The Medical - Drugs industry, to which Assertio belongs, is currently ranked in the bottom 42% of over 250 Zacks industries, indicating potential challenges ahead [8]

Earnings Call InsightsAssertio outlines $110M–$125M 2026 revenue target with Rolvedon at the core while shifting business development approachMar. 16, 2026 6:03 PM ETAssertio Holdings, Inc. (ASRT) StockAI-Generated Earnings Calls InsightsCommentsEarnings Call Insights: Assertio Holdings, Inc. (ASRT) Q4 2025 Management View CEO Mark L. Reisenauer emphasized a shift in Assertio’s growth strategy, stating the company will prioritize driving "significant revenue opportunity in our core asset, Rolvedon," and tha ...

Assertio (NasdaqCM:ASRT) Q4 2025 Earnings call March 16, 2026 04:30 PM ET Company ParticipantsAjay Patel - CFODaniel Santos - SVPMark Reisenauer - CEOPaul Schwichtenberg - President and COORaghuram Selvaraju - Managing DirectorScott Henry - Managing DirectorConference Call ParticipantsNazibur Rahman - VP and Equity Research AnalystThomas Flaten - Senior Research AnalystOperatorLadies and gentlemen, thank you for standing by. My name is Abby, and I will be your conference operator today. At this time, I woul ...

Assertio (NasdaqCM:ASRT) Q4 2025 Earnings call March 16, 2026 04:30 PM ET Speaker4Ladies and gentlemen, thank you for standing by. My name is Abby, and I will be your conference operator today. At this time, I would like to welcome everyone to the Assertio Holdings Fourth Quarter and Full Year 2025 Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during th ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39294 ASSERTIO HOLDINGS, INC. (Exact Name of Registrant as Specified in its Charter) INCORPORATION OR ORGANIZATION) (I.R.S. EMPLOYER IDENTIFICA ...

Assertio Reports Fourth Quarter and Full Year 2025 Financial Results Assertio Reports Fourth Quarter and Full Year 2025 Financial Results Share Delivers FY2025 Net Product Sales and Adjusted EBITDA Above Guidance Expects Net Product Sales between $110M-$125M and Adjusted EBITDA between $28M-$40M in FY2026 LAKE FOREST, Ill--(BUSINESS WIRE)--Assertio Holdings, Inc. ("Assertio†or the "Company†) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated product ...

Group 1 - Assertio (ASRT) is a notable stock in the Medical sector, currently outperforming its peers with a year-to-date return of 31.2% compared to the sector average of 0.5% [4] - The Zacks Rank for Assertio is 2 (Buy), indicating a favorable outlook based on earnings estimate revisions and improving earnings prospects [3] - Over the past 90 days, the Zacks Consensus Estimate for Assertio's full-year earnings has increased by 6.6%, reflecting stronger analyst sentiment [4] Group 2 - Assertio is part of the Medical - Drugs industry, which consists of 143 companies and currently ranks 87 in the Zacks Industry Rank, while the industry has seen an average loss of 1.3% this year [6] - Another outperforming stock in the Medical sector is Aura Biosciences, Inc. (AURA), which has gained 14.5% year-to-date and has a Zacks Rank of 2 (Buy) [5] - The Medical - Biomedical and Genetics industry, where Aura operates, has 447 stocks and has increased by 6.6% since the beginning of the year [7]

Core Viewpoint - Assertio Holdings, Inc. is set to release its fourth quarter and full year 2025 financial results on March 16, 2026, after market close [1] Financial Results Announcement - The financial results will be followed by a live webcast of the earnings conference call at 4:30 p.m. Eastern Time [1] - Access to the live webcast, conference call information, and additional materials will be available on Assertio's investor relations page [1]

Group 1 - Assertio (ASRT) shares have increased by 28.9% over the past four weeks, closing at $11.78, with a mean price target of $38.94 indicating a potential upside of 230.6% [1] - The average price targets range from a low of $24.74 to a high of $45.00, with a standard deviation of $9.04, suggesting a significant potential increase from the current price level [2] - Analysts show strong agreement on ASRT's ability to report better earnings, with a positive trend in earnings estimate revisions correlating with potential stock price increases [4][11] Group 2 - The Zacks Consensus Estimate for ASRT's current year earnings has increased by 6.6% over the last 30 days, indicating positive sentiment among analysts [12] - ASRT holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates, suggesting strong potential for upside [13] - While consensus price targets may not be entirely reliable, the direction they imply appears to be a good guide for potential price movement [14]

Company Overview - ADC Therapeutics SA (ADCT) is a notable stock within the Medical group, which comprises 929 companies and holds the 10 position in the Zacks Sector Rank [2] - The Zacks Rank system focuses on earnings estimates and revisions to identify stocks with improving earnings outlooks, with ADC Therapeutics currently rated 2 (Buy) [3] Performance Analysis - Over the past three months, the Zacks Consensus Estimate for ADCT's full-year earnings has increased by 24.9%, indicating improved analyst sentiment and a more positive earnings outlook [4] - Year-to-date, ADC Therapeutics has returned 6.5%, outperforming the Medical sector's average return of 6% [4] - In comparison to its specific industry, Medical - Biomedical and Genetics, which has gained about 21.1% this year, ADCT is slightly underperforming [6] Industry Context - The Medical - Biomedical and Genetics industry includes 450 stocks and is currently ranked 88 in the Zacks Industry Rank [6] - Another stock, Assertio (ASRT), has significantly outperformed the sector with a year-to-date return of 29.3% and is rated 1 (Strong Buy) [5] - The Medical - Drugs industry, where Assertio belongs, has 141 stocks and has seen a modest increase of 2.9% this year [7]